We noticed you are on our Australia page. Want to switch regions? Choose from the options:
You may leave me a review on these links:
We’re dedicated to breaking boundaries through clinical studies and to finding new and improved ways to treat cancer that deliver better life outcomes for our patients
A PHASE 2, RANDOMIZED, OPEN-LABEL STUDY OF ENCORAFENIB AND CETUXIMAB PLUS PEMBROLIZUMAB VERSUS PEMBROLIZUMAB ALONE IN PARTICIPANTS WITH PREVIOUSLY UNTREATED BRAFV600E-MUTANT, MSI-H/DMMR METASTATIC COL
Basket – Solid Tumours
A Phase 1b/2, Master Protocol Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 510 (pINN Sotorasib) in Subjects With Advanced Solid Tumours With KRAS p.G12C Mutation
A Phase 3, Randomized, Open-Label, Controlled Study of Cabozantinib (XL184) in Combination with Atezolizumab vs Second Novel Hormonal Therapy (NHT) in Subjects with Metastatic Castration-Resistant Pro
Therapeutic Group: Non-Melanoma Skin Cancer
The aim of this study is to assess the efficacy of delivering chemotherapy treatment through the arteries directly to the liver, bypassing the main blood supply throughout the body.
Kidney (Genitourinary) Cancer
Darolutamide + Consolidation Radiotherapy in Advanced Prostate Cancer detected by PSMA.
To evaluate the efficacy and safety of a new valve in patients with severe, symptomatic aortic stenosis.
To evaluate the efficacy and safety on a new drug in participants with Mixed Dyslipidaemia.
To evaluate a new device in patients with prior acute coronary syndrome.
To evaluate if treatment with a new drug reduces the risk cardiovascular disease in patients with established cardiovascular disease, chronic kidney disease and inflammation.
To evaluate a new mitral valve replacement in patients who moderate-severe or severe mitral regurgitation at a high surgical risk.
To evaluate a new medication for the treatment of patients with Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM).
To evaluate the efficacy and safety of a new drug on morbidity and mortality in participants with heart failure (NYHA II-IV) and left ventricular ejection fraction ≥40% (LVEF ≥40%).
Irregular Heart Beat
Clinical trial of patients with AF and their acceptability of MultiPulse Therapy (low voltage energy used to terminate tachyarrhythmias) prior to their clinically indicated electrophysiology procedure
Clinical Trial of Atrial Fibrillation Patients Comparing Left Atrial Appendage Occlusion Therapy to Non-vitamin K Antagonist Oral Anticoagulants.
A Prospective Registry Study to Evaluate the Effect of the DCISionRT Test on Treatment Decisions in Patients with DCIS Following Breast Conserving Therapy.
A Study of Chemo Only Versus Chemo Plus Nivo With or Without BMS-986205, Followed by Post- Surgery Therapy With Nivo or Nivo and BMS-986205 in Patients With MIBC.
Non-melanoma Skin Cancer
Evaluation of Oedema and lymphatic function following volumetric modulated arc therapy for non-melanoma extensive skin field cancerisation of the lower limbs.
The aim of this study is to determine the safety and tolerability of 64Cu-SARbisPSMA in participants with untreated, confirmed Prostate Cancer.
The hypothesis of study is addition of apalutamide to RT+ LHRHa provides superior efficacy in terms of PSMA-PET metastatic progression-free survival-ppMPFS.
This is a prospective, multicentre randomised, phase II clinical trial, with randomisation 2:1 by minimisation and stratification by tumour stage, planned chemotherapy and institution.
This study will consist of four groups with the initial three groups undergoing dose escalation and the fourth group will be to confirm the optimal dose and imaging conditions.
A comparison of two routinely used skin treatments for women with breast cancer undergoing radiation therapy.
The purpose of this study is to determine the effect of androgen deprivation therapy, a treatment commonly prescribed in prostate cancer patients, on the effectiveness of medical imaging techniques.
The NINJA clinical trial aims to compare two emerging schedules of radiotherapy in the treatment of prostate cancer.
The purpose of this trial is to see if a reduced radiotherapy can deliver equivalent treatment response to full dose radiotherapy for patients with skin cancer.
A Randomized, Placebo-Controlled, Double-Blind Study of Adjuvant Cemiplimab Versus Placebo After Surgery and Radiation Therapy in Patients With High Risk Cutaneous Squamous Cell Carcinoma.
This study aims to clinically validate use of the Baker Skin Field Cancerisation Tool (BSFCT) in people attending St Vincent’s Hospital Melbourne dermatology clinic.
Stereotactic Radiotherapy for Oligoprogressive ER-positive Breast Cancer (AVATAR).
A Long-Term, Prospective and Retrospective, Observational Registry Assessing Technical Data and Clinical Outcomes Following Treatment with MR-Linac.
Phase II targeted therapy or immunotherapy guided by genomic profiling versus platinum based chemotherapy (3C) (after receiving three cycles of platinum based chemotherapy).
This study will examine the efficacy and safety of trastuzumab deruxtecan compared with trastuzumab emtansine in high-risk patients with residual invasive breast cancer following neoadjuvant therapy.
Metastatic Kidney Cancer
This study is designed to test the safety and potential benefit of adding an existing drug used for bone protection (denosumab) to a new immune stimulating drug (pembrolizumab).
Adding mitomycin C to BCF as adjuvant intravesical therapy for high-risk, non muscle invasive bladder cancer, a randomised phase 3 trial.
Assess the antitumor efficacy and safety of pembrolizumab in combination with chemoradiotherapy (CRT) versus CRT alone in participants with muscle-invasive bladder cancer (MIBC).
A Phase III Study of the Impact of a Physical Activity Program on Disease-Free Survival in Patients With High-Risk Stage II or Stage III Colon Cancer: A Randomized Controlled Trial
The aim of this study is to compare treatment informed by ctDNA results to standard care in patients with stage III colon cancer.
The purpose of this study is to see whether adding durvalumab to standard chemotherapy will improve overall survival (OS) in patients with MPM.
Carcinoma, Non-Small-Cell Lung
A Phase 1b/2 Open Label Umbrella Study of Sasanlimab Combined With Anti-Cancer Therapies Targeting Multiple Molecular Mechanisms in Participants With Non-Small Cell Lung Cancer (NSCLC).
Non-small Cell Lung Cancer
The purpose of the study is to compare progression-free survival between Arm A and Arm B as assessed by investigators according to Response Evaluation Criteria in Solid Tumors Version 1.1.
Carcinoma, Non- Small Cell Lung
This is a Phase III double-blind, placebo-controlled study of Durvalumab versus Placebo in patients with stage II-III NSCLC who are MRD-positive following curative intent therapy.
The purpose of this study is to assess the efficacy and safety of durvalumab versus placebo following SoC chemotherapy in patients with completely resected stage II-III NSCLC who are MRD+ post surgery
The purpose of this study is to see if a new drug, darolutamide, combined with the current best treatments, can improve outcomes for people with prostate cancer.
This study will assess the efficacy and safety of darolutamide in combination with standard androgen deprivation therapy (ADT) in patients with metastatic hormone sensitive prostate cancer.
Investigate the activity and safety of adding Lu-PSMA to enzalutamide in patients with metastatic castrate resistant prostate cancer (mCRPC) not previously treated with chemotherapy.
To collect data and evaluate the safety of Cardiac Resynchronisation Therapy (CRT) by utilising new techniques and investigational systems for patients in heart failure.
Connective Tissue Disorders
GenesisCare is recruiting patients with Dupuytren’s Disease for a research study called ‘DEPART’.
Aortic Valve Stenosis
To evaluate a new valve, the Portico™ NG Transcatheter Aortic Heart Valve, in patients who have symptomatic, severe aortic stenosis and are determined to be at high or extreme surgical risk.
Heart Failure due to mitral valve regurgitation
To evaluate a new valve in patients with moderate-severe or severe mitral regurgitation and at high surgical risk.
Early Breast Cancer
A unique opportunity to improve personalised use of radiation therapy in patients with early breast cancer according to their individual risks of local recurrence.
To evaluate if treatment with two cardioprotective medications reduces the risk of developing heart failure in participants currently undergoing chemotherapy.
To collect data to evaluate specified outcomes for patients undergoing radiotherapy for skin cancer and inflammatory skin conditions.